Pyxis Oncology is trading 9.1% up at $2.89 in pre-market action, rebounding from Friday’s pullback despite a lack of fresh company-specific catalysts.
- The move appears to follow last week’s technical volatility and a broader risk-on sentiment in U.S. equities rather than new fundamental developments.
- No new SEC filings, press releases, or analyst calls have been issued to account for the overnight price movement.